<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02404168</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00063848</org_study_id>
    <nct_id>NCT02404168</nct_id>
  </id_info>
  <brief_title>BEEP Follow Up: Evaluation of Repeatability of Lamotrigine Pharmacokinetics in Epileptic Patients</brief_title>
  <official_title>Evaluation of Repeatability of Lamotrigine Pharmacokinetics in Epileptic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prior BEEP study involved patients being switched between brand and generic in a very
      structured manner. Other secondary comparisons were also made (i.e. any differences in
      adverse effects and seizure control). Some subjects were more disparate than other, in terms
      of generic being similar to brand. In this follow up study, BEEP subjects that showed
      disparate results will be tested again to assess reproducibility of disparate results.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an double-blind, multiple-dose, full replicate design, pharmacokinetic study of
      lamotrigine in &quot;enriched&quot; patients with epilepsy who previously participated in HP-00048923.
      LAMICTAL 100mg tablets and the most commonly used generic lamotrigine 100mg tablet (from
      Teva) will be compared pharmacokinetically.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 7, 2015</start_date>
  <completion_date type="Actual">April 6, 2016</completion_date>
  <primary_completion_date type="Actual">January 18, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>0-12hr</time_frame>
    <description>pharmacokinetic exposure (ng*hr/ml). Pharmacokinetic (PK) blood levels will be drawn at the schedule times: immediately prior to lamotrigine administration, then after drug administration at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 10.0, and 12.0 hr.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>0-12hr</time_frame>
    <description>pharmacokinetic rate (ng/ml). Pharmacokinetic (PK) blood levels will be drawn at the schedule times: immediately prior to lamotrigine administration, then after drug administration at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 10.0, and 12.0 hr.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>lamotrigine brand tablet1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>lamotrigine tablet Lamictal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lamotrigine generic tablet1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lamotrigine tablet Teva</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lamotrigine brand tablet2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>lamotrigine tablet Lamictal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lamotrigine generic tablet2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lamotrigine tablet Teva</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lamotrigine (brand Lamictal)</intervention_name>
    <description>an anti-epileptic drug (brand)</description>
    <arm_group_label>lamotrigine brand tablet1</arm_group_label>
    <arm_group_label>lamotrigine brand tablet2</arm_group_label>
    <other_name>Lamictal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lamotrigine (generic Teva)</intervention_name>
    <description>an anti-epileptic drug (brand)</description>
    <arm_group_label>lamotrigine generic tablet1</arm_group_label>
    <arm_group_label>lamotrigine generic tablet2</arm_group_label>
    <other_name>generic lamotrigine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is able to provide informed consent and was enrolled in previous BEEP study.

          -  Subject is male or female between 18 and 76 years of age inclusive.

          -  Subject has a diagnosis of epilepsy with simple partial seizures and/or complex
             partial seizures, with or without secondary generalization or primary generalized
             seizures

          -  Subject has been maintained on a stable dose regimen of anti-epileptic drugs (AEDs),
             including lamotrigine at 200mg, 400mg, or 600mg total daily dosage divided BID for at
             least 8 weeks prior to Visit 1 and during the screening period

          -  Subject is willing to be switched between brand and generic lamotrigine

          -  Subject is an acceptable candidate for venipuncture

          -  Subject is willing to stop all OTC medications for 24 hours prior to and during 12
             hour study visits

        Exclusion Criteria:

          -  Subject is currently participating or has participated within the last 2 months in any
             trial of an investigational drug or experimental device

          -  Subject has a history of status epilepticus within the 12 month period prior to Visit
             1.

          -  Subject has any medical condition, which in the opinion of the investigator, could
             jeopardize the subject's health or would compromise the subject's ability to
             participate in the trial

          -  Subject has any psychiatric condition, which in the opinion of the investigator, could
             jeopardize the subject's health or would compromise the subject's ability to
             participate in this trial or confound the interpretation of the trial data

          -  Subject has known hypersensitivity to lamotrigine

          -  Subject has a medical condition that impacts drug absorption (e.g. gastric bypass
             surgery), including routine use (i.e.

        daily or weekly) use of acid blockers, antacids, anti-diarrhea, stimulants, appetite
        suppressants, or anti nausea medication or other drugs that modulate GI function

          -  Subject has any history of alcohol or drug abuse within the previous two years

          -  Subject has acute or subacutely progressive CNS disease

          -  Subject has moderate or severe liver impairment as assessed by alanine
             aminotransferase (ALT), aspartate aminotransferase (AST), or total bilirubin levels â‰¥5
             times the upper limit of normal (ULN).

          -  Subject has moderate or severe renal impairment as assessed by creatinine clearance
             lower than 50mL/min, using the Cockcroft-Gault formula

          -  Female subjects of childbearing potential will not be eligible to participate who are
             unwilling or unable to use a medically acceptable method of contraception throughout
             the entire study period and for one week after the study is completed. Medically
             acceptable methods of contraception that may be used by the subject and/or her partner
             are: condom with spermicide, diaphragm with spermicide, IUD without progesterone,
             vaginal spermicidal suppository, surgical sterilization of their partner(s) or
             abstinence

          -  Female subject is pregnant or nursing

          -  Female subject is using hormonal contraceptive precautions including
             progesterone-coated IUD

          -  Subjects is using hormonal replacement therapy

          -  Subject is unwilling or unable to maintain their approximate daily smoking use during
             the study

          -  Subject is using rifampin or other non-AED that strongly modulates lamotrigine levels

          -  addition to lamotrigine and/or vagus nerve stimulation and/or intermittent
             benzodiazepine use (e.g. lorazepam, diazepam, clonazepam), subject is taking more than
             two concomitant AEDs

          -  Subject is not willing or able to be adherent to study protocol (e.g. dosing of
             lamotrigine and any interacting comedication).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>76 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Andermann F, Duh MS, Gosselin A, Paradis PE. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia. 2007 Mar;48(3):464-9.</citation>
    <PMID>17346246</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>March 17, 2015</study_first_submitted>
  <study_first_submitted_qc>March 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2015</study_first_posted>
  <results_first_submitted>April 24, 2019</results_first_submitted>
  <results_first_submitted_qc>April 24, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 15, 2019</results_first_posted>
  <last_update_submitted>August 15, 2019</last_update_submitted>
  <last_update_submitted_qc>August 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>James E Polli</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamotrigine</mesh_term>
    <mesh_term>Anticonvulsants</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lamotrigine Tablet</title>
          <description>Sequence: generic first, then brand, then brand, and then generic. Each of the four arms will be about two weeks in duration. During the study, subjects will receive their on-going therapeutic lamotrigine regimen of either 200mg, 400mg, or 600mg total daily dosage, divided in twice-a-day doses (i.e. every 12 hours). In the study, 100mg lamotrigine tablets (brand or generic) will be dispensed to the subject at the start of each study arm.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lamotrigine Tablet</title>
          <description>Sequence: generic first, then brand, then brand, and then generic</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" lower_limit="22" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUC</title>
        <description>pharmacokinetic exposure (ng*hr/ml). Pharmacokinetic (PK) blood levels will be drawn at the schedule times: immediately prior to lamotrigine administration, then after drug administration at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 10.0, and 12.0 hr.</description>
        <time_frame>0-12hr</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Comparator: Lamotrigine Brand</title>
            <description>lamotrigine tablet Lamictal</description>
          </group>
          <group group_id="O2">
            <title>Experimental: Lamotrigine Generic</title>
            <description>lamotrigine tablet Teva</description>
          </group>
        </group_list>
        <measure>
          <title>AUC</title>
          <description>pharmacokinetic exposure (ng*hr/ml). Pharmacokinetic (PK) blood levels will be drawn at the schedule times: immediately prior to lamotrigine administration, then after drug administration at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 10.0, and 12.0 hr.</description>
          <units>ng*hr/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79640" spread="11442"/>
                    <measurement group_id="O2" value="81653" spread="11991"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax</title>
        <description>pharmacokinetic rate (ng/ml). Pharmacokinetic (PK) blood levels will be drawn at the schedule times: immediately prior to lamotrigine administration, then after drug administration at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 10.0, and 12.0 hr.</description>
        <time_frame>0-12hr</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Comparator: Lamotrigine Brand</title>
            <description>lamotrigine tablet Lamictal</description>
          </group>
          <group group_id="O2">
            <title>Experimental: Lamotrigine Generic</title>
            <description>lamotrigine tablet Teva</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax</title>
          <description>pharmacokinetic rate (ng/ml). Pharmacokinetic (PK) blood levels will be drawn at the schedule times: immediately prior to lamotrigine administration, then after drug administration at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 10.0, and 12.0 hr.</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8836" spread="1245"/>
                    <measurement group_id="O2" value="9024" spread="1203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Active Comparator: Lamotrigine Brand</title>
          <description>lamotrigine tablet Lamictal</description>
        </group>
        <group group_id="E2">
          <title>Experimental: Lamotrigine Generic</title>
          <description>lamotrigine tablet Teva</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This was a small study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>James Polli</name_or_title>
      <organization>University of Maryland</organization>
      <phone>410-706-8292</phone>
      <email>jpolli@rx.umaryland.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

